INNOVENT BIOLOGICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.68 USD | +0.92% |
|
-0.35% | -5.79% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 29,957 | 96,872 | 57,482 | 45,398 | 63,018 | 55,757 | - | - |
| Enterprise Value (EV) 1 | 26,589 | 89,793 | 50,957 | 39,338 | 56,487 | 50,963 | 51,594 | 51,425 |
| P/E ratio | -16.3 x | -93.3 x | -18.2 x | -20.3 x | -58.9 x | -65.4 x | 731 x | 41.1 x |
| Yield | - | - | - | - | - | - | 0.01% | - |
| Capitalization / Revenue | 28.6 x | 25.2 x | 13.5 x | 9.96 x | 10.2 x | 7.32 x | 5.59 x | 4.31 x |
| EV / Revenue | 25.4 x | 23.4 x | 11.9 x | 8.63 x | 9.1 x | 6.69 x | 5.17 x | 3.98 x |
| EV / EBITDA | -16.2 x | -370 x | -16.7 x | -14.3 x | -94.1 x | -99.2 x | 109 x | 27.3 x |
| EV / FCF | -13.1 x | -113 x | -16.5 x | -14 x | -58.1 x | -41.4 x | -202 x | 50 x |
| FCF Yield | -7.64% | -0.89% | -6.06% | -7.16% | -1.72% | -2.41% | -0.5% | 2% |
| Price to Book | 5.87 x | 10.7 x | 5.54 x | 4.11 x | 4.84 x | 4.54 x | 4.68 x | 4.24 x |
| Nbr of stocks (in thousands) | 1,262,562 | 1,402,776 | 1,462,109 | 1,534,407 | 1,621,831 | 1,628,023 | - | - |
| Reference price 2 | 23.73 | 69.06 | 39.31 | 29.59 | 38.86 | 34.25 | 34.25 | 34.25 |
| Announcement Date | 3/30/20 | 3/29/21 | 3/29/22 | 3/28/23 | 3/20/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,048 | 3,844 | 4,270 | 4,556 | 6,206 | 7,619 | 9,971 | 12,935 |
| EBITDA 1 | -1,638 | -242.4 | -3,045 | -2,747 | -600.1 | -513.9 | 471.7 | 1,885 |
| EBIT 1 | -1,676 | -310.4 | -3,113 | -3,066 | -1,679 | -922.2 | 56.69 | 1,536 |
| Operating Margin | -159.96% | -8.08% | -72.9% | -67.29% | -27.06% | -12.1% | 0.57% | 11.88% |
| Earnings before Tax (EBT) 1 | -1,720 | -858.7 | -3,051 | -2,170 | -1,144 | -819.1 | 105.3 | 1,621 |
| Net income 1 | -1,720 | -998.4 | -3,138 | -2,179 | -1,028 | -842 | 51.01 | 1,366 |
| Net margin | -164.2% | -25.97% | -73.5% | -47.83% | -16.56% | -11.05% | 0.51% | 10.56% |
| EPS 2 | -1.460 | -0.7400 | -2.160 | -1.460 | -0.6600 | -0.5239 | 0.0469 | 0.8324 |
| Free Cash Flow 1 | -2,030 | -796.7 | -3,090 | -2,816 | -971.6 | -1,230 | -255.7 | 1,030 |
| FCF margin | -193.83% | -20.73% | -72.38% | -61.8% | -15.66% | -16.15% | -2.56% | 7.96% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 54.6% |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | 75.35% |
| Dividend per Share 2 | - | - | - | - | - | - | 0.002860 | - |
| Announcement Date | 3/30/20 | 3/29/21 | 3/29/22 | 3/28/23 | 3/20/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 702 | 984.2 | 2,860 | 1,942 | 2,328 | 2,240 | 2,317 | 2,702 | 3,505 | 3,728 | 4,119 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | -1,148 | -1,960 | -1,212 | -1,617 | -718.8 | -960.5 | -696.6 | -1,025 |
| Operating Margin | - | - | - | -59.12% | -84.17% | -54.11% | -69.8% | -26.61% | -27.41% | -18.69% | -24.89% |
| Earnings before Tax (EBT) | - | - | - | - | -1,876 | -998.9 | -1,172 | -256.1 | -888.3 | - | - |
| Net income | - | - | - | - | -1,963 | -950.5 | -1,229 | -139.1 | -888.8 | - | - |
| Net margin | - | - | - | - | -84.31% | -42.43% | -53.04% | -5.15% | -25.36% | - | - |
| EPS 2 | -0.8400 | -0.4600 | -0.2800 | -0.8100 | -1.350 | -0.6500 | -0.8100 | -0.0900 | -0.5700 | -0.3000 | -0.5100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 8/26/20 | 3/29/21 | 8/25/21 | 3/29/22 | 8/25/22 | 3/28/23 | 8/23/23 | 3/20/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 3,368 | 7,079 | 6,525 | 6,059 | 6,530 | 4,795 | 4,163 | 4,333 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -2,030 | -797 | -3,090 | -2,816 | -972 | -1,230 | -256 | 1,030 |
| ROE (net income / shareholders' equity) | -38.4% | -14.8% | -32.8% | -20.7% | -8.84% | -6.69% | 0.74% | 9.42% |
| ROA (Net income/ Total Assets) | -25.8% | -10.5% | -22.4% | -12.9% | -5.38% | -3.92% | 0.89% | 5.8% |
| Assets 1 | 6,672 | 9,533 | 14,039 | 16,916 | 19,108 | 21,469 | 5,715 | 23,579 |
| Book Value Per Share 2 | 4.040 | 6.470 | 7.100 | 7.200 | 8.030 | 7.540 | 7.320 | 8.080 |
| Cash Flow per Share 2 | -1.410 | -0.2300 | -1.390 | -1.290 | 0.0900 | -0.4900 | 0.2000 | 1.020 |
| Capex 1 | 366 | 489 | 1,066 | 897 | 1,119 | 658 | 678 | 689 |
| Capex / Sales | 34.93% | 12.72% | 24.96% | 19.68% | 18.04% | 8.63% | 6.8% | 5.33% |
| Announcement Date | 3/30/20 | 3/29/21 | 3/29/22 | 3/28/23 | 3/20/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
34.25
CNY
Average target price
51.68
CNY
Spread / Average Target
+50.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.99% | 95.18B | |
| -4.34% | 37.55B | |
| -10.41% | 33.75B | |
| +75.79% | 28.2B | |
| -14.61% | 15.63B | |
| -3.46% | 13.63B | |
| -12.31% | 11.5B | |
| +184.77% | 10.81B | |
| -54.13% | 9.23B |
- Stock Market
- Equities
- 1801 Stock
- IVBIY Stock
- Financials Innovent Biologics, Inc.
